Galleri Multi-Cancer Blood Test Fails to Meet Key Clinical Trial Goals
In a significant development in oncology research, a groundbreaking blood test intended to detect more than 50 types of cancer has not met its primary objectives in a large-scale clinical trial. Results from this pivotal study were shared at the recent American Society of Clinical Oncology (ASCO) annual meeting in Chicago, raising questions about the effectiveness of the Galleri multi-cancer early detection (MCED) test.
The trial, which enrolled 142,942 participants aged 50 to 77 with no existing cancer symptoms, aimed to evaluate whether the incorporation of the Galleri test into standard cancer screening processes could lead to earlier cancer diagnoses, ultimately enabling treatment at more manageable stages. Despite its ambitious goals, the trial did not achieve its primary endpoint: a statistically significant reduction in late-stage cancer diagnoses.
Dr. Julie Gralow, ASCO’s Chief Medical Officer, acknowledged some positive trends in tumor downstaging but emphasized that the trial did not demonstrate a meaningful decrease in late-stage cancers as initially aimed. She stated, “While the Galleri-NHS study results show some encouraging trends, it is crucial to recognize that the trial did not statistically reduce late-stage cancers by its predefined primary endpoint.” This sentiment was echoed by a senior cancer expert present at the conference, who bluntly commented, “The trial flopped—clear and simple.”
Trial Overview and Methodology
Participants in the trial were divided into two groups: half received the Galleri blood test, while the other half underwent only standard cancer screening. Blood samples were collected annually over three years, and any positive results from the Galleri test prompted a follow-up for diagnostic evaluation. The key focus was to compare the occurrence of stage three and four cancer diagnoses between those who underwent Galleri testing and those who did not.
Despite initial hopes, the findings indicated no statistically significant decrease in advanced cancer cases among those screened with Galleri. The trial’s primary goal of showing a reduction in late-stage cancer diagnoses among various cancer types was unmet.
Mixed Reactions and Future Considerations
Although Grail, the California-based company behind the Galleri test, pointed to some encouraging secondary findings—particularly a 14% decrease in stage four cancer cases—many experts remain skeptical. Harpal Kumar, Grail’s Chief Scientific Officer, highlighted the potential of Galleri to transform cancer detection, yet independent researchers urge caution.
Prof. Richard Houlston, Head of the Division of Genetics and Epidemiology at the Institute of Cancer Research, London, stressed that while the study provides valuable data, it has been framed more optimistically than warranted. He noted, “The failure to meet the primary endpoint is the crux of the issue here. Mortality outcomes will be available in a couple of years, examination of which will be warranted.” Furthermore, he indicated that there is currently no robust evidence to justify the implementation of the Galleri test on a population-wide scale based on the results of this trial and smaller studies.
Prof. Peter Johnson, National Clinical Director for Cancer at NHS England, expressed anticipation for a comprehensive analysis of the trial data to guide future decisions regarding Galleri’s potential role in the NHS.
Conclusion
The recent findings from the Galleri clinical trial underscore the complexities inherent in advancing cancer detection methodologies. While the Galleri test may hold promise for future applications, the lack of success in meeting its primary objective necessitates further investigation and thoughtful consideration before potential large-scale implementation. As the oncology community continues to explore innovative detection strategies, the results from this landmark trial will play a crucial role in shaping future research and clinical practices.
